METTL5 and Miyoshi myopathy: Given the effectiveness and safety of SAC in vitro and in vivo in treating MM by targeting METTL5 to inhibit protein translation efficiency, we suggest that SAC may be a promising drug for treating MM patients, particularly those exhibiting high METTL5 expression.